The review lays out how GLP-1 agonists may affect blood pressure and lipid handling, and why that could matter for heart risk.
Recap by typeshit. Full story at Clinical Advisor.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Ricks describes working with the Trump administration to lower obesity drug costs for older Americans, on the day Lilly posted third-quarter earnings.
Medscape covers a comparison in a diverse group of patients with obesity where bariatric surgery outperformed tirzepatide. Full results are at the link.
Loading…